CLINICAL-STUDY OF NIBENTAN - NEW CLASS-II I ANTIARRHYTHMIC DRUG .2. EFFICACY IN PATIENTS WITH SUPRAVENTRICULAR ARRHYTHMIAS

Efficacy of a new class III antiarrhythmic drug nibentan was studied i n 43 patients with different cardiac disease. Intravenous application of the drug (0,125 - 0,375 mg/kg in 1 - 3 boluses) produced pronounced antiarrhythmic effect in 100% of patients with attacks of supraventri cular tachycardia, in 100% of patients with attacks of atrial flutter and in 72,7% - of atrial fibrillation. In permanent atrial flutter eff icacy was 90% and in permanent fibrillation - 83,3%. Nibentan was less effective for suppression of atrial premature beats. Mean effective d oses of nibentan varied from 0,15+/-0,025 to 0,23+/-0,048 mg/kg depend ing on type of arrhythmia with tendency to higher doses in permanent c ompared to paroxysmal atrial flutter and fibrillation. Results of the study showed that the dose of nibentan should be increased gradually a nd its starting dose should not exceed 0,125 mg/kg.